The Biden administration announced Friday that Ozempic, Wegovy and 13 additional drugs will now be covered under Medicare Part-D for price negotiations, the next round of negotiations under the Inflation Reduction Act passed by President Joe Biden in 2022.

Federal officials are targeting the blockbuster drugs as part of their ongoing initiative to lower drug costs.

Diabetes and weight loss drugs Ozempic and Wegovy have been added to the list of medications selected for Medicare price negotiations, federal health officials announced Friday. The negotiations for the 15 additional drugs, which will be handled by the incoming administration, assure major savings for Americans.